Granuloma Annulare Secondary to Vemurafenib Therapy for Lung Adenocarcinoma.
Numerous cutaneous manifestations have been associated with use of BRAF inhibitors, including two previously reported cases of granuloma annulare (GA) eruptions associated with vemurafenib therapy. Both of these patients were being treated for metastatic melanoma. In this report, we describe the case of a 71-year-old man who developed classic GA lesions while being treated with vemurafenib monotherapy for nonmelanoma cancer, specifically metastatic lung adenocarcinoma positive for BRAF V600 mutation. <p><em>J Drugs Dermatol. 2017;16(10):1050-1052.</em></p>.